去纤苷适合什么人用呢？

Defibrotide (defiteli) was first developed by Gentium Pharmaceuticals in Italy and was approved for marketing in the EU in October 2013. After Gentium Pharmaceuticals was acquired by Jazz Pharmaceuticals of the United States, defiteli (defiteli) was approved by the US Food and Drug Administration (FDA) to be launched in the United States on March 30, 2016, under the trade name Defitelio.

Who is defibrinoside (defiteli, defiteli) suitable for? We all know that defibrotide (defiteli) is an effective drug suitable for the treatment of hepatic veno-occlusive disease, and patients have chosen defibrotide (defiteli).

Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. Defibrotide is a mixture of single-stranded oligonucleotides with antithrombotic and fibrinolytic effects. At present, multiple clinical research results indicate that defibrotide (defiteli) is a safe and effective drug for preventing and treating HVOD after HSCT.

Defibrotide (defiteli) should be used under the guidance of a doctor. The recommended dose of defibrotide for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrotide until resolution of VOD or up to a maximum of 60 days.

Defibrotide (defiteli) has ideal therapeutic effect and is the best choice for patients with hepatic veno-occlusive disease. If you have any other questions, please consult the medical companion passenger service.